ApoE: Crossroads between Alzheimer's disease and atherosclerosis

Seminars in Vascular Medicine

Volumn 4, Issue 3, 2004, Pages 279-285

  Stojakovic, Tatjana ^a   Scharnagl, Hubert ^a   März, Winfried ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Alzheimer's disease; Amyloid; Apolipoprotein E; Atherosclerosis

Indexed keywords

AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; ISOPROTEIN; LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ALZHEIMER DISEASE; BINDING AFFINITY; BRAIN ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; GENETIC POLYMORPHISM; HOMOZYGOSITY; HUMAN; HYPERLIPOPROTEINEMIA TYPE 3; LIPOPROTEIN METABOLISM; NERVE CELL; NEUROPATHOLOGY; ONSET AGE; PROTEIN BINDING; PROTEIN DEGRADATION; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; BRAIN; HUMANS; LIPOPROTEINS; POLYMORPHISM, GENETIC; SENILE PLAQUES;

EID: 11844258247     PISSN: 15289648     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-861496     Document Type: Review

References (90)

1. Sloane PD, Zimmerman S, Suchindran C, et al. The public health impact of Alzheimer's disease, 2000-2050: potential implication of treatment advances. Annu Rev Public Health 2002;23:213-231
2. Yankner BA. A century of cognitive decline. Nature 2000;404:125
3. Lautenschlager NT, Cupples LA, Rao VS, et al. Risk of dementia among relatives of Alzheimer's disease patients in the MIRAGE study: what is in store for the oldest old? Neurology 1996;46:641-650
4. Mohs RC, Breitner JC, Silverman JM, Davis KL. Alzheimer's disease. Morbid risk among first-degree relatives approximates 50% by 90 years of age. Arch Gen Psychiatry 1987;44:405-408
5. Ott A, Slooter AJ, Hofman A, et al. Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study. Lancet 1998;351:1840-1843
6. Ott A, Stolk RP, van Harskamp F, et al. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 1999;53:1937-1942
7. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001;322:1447-1451
8. St George-Hyslop PH. Molecular genetics of Alzheimer's disease. Biol Psychiatry 2000;47:183-199
9. Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol 1985;42:1097-1105
10. Tierney MC, Fisher RH, Lewis AJ, et al. The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease: a clinicopathologic study of 57 cases. Neurology 1988;38:359-364
11. Haass C, Schlossmacher MG, Hung AY, et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 1992;359:322-325
12. Shoji M, Golde TE, Ghiso J, et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 1992;258:126-129
13. Hung AY, Selkoe DJ. Selective ectodomain phosphorylation and regulated cleavage of beta-amyloid precursor protein. EMBO J 1994;13:534-542
14. Walter J, Capell A, Hung AY, et al. Ectodomain phosphorylation of beta-amyloid precursor protein at two distinct cellular locations. J Biol Chem 1997;272:1896-1903
15. Weidemann A, Konig G, Bunke D, et al. Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. Cell 1989;57:115-126
16. Kang J, Lemaire HG, Unterbeck A, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987;325:733-736
17. Qiu WQ, Ferreira A, Miller C, Koo EH, Selkoe DJ. Cell-surface beta-amyloid precursor protein stimulates neurite outgrowth of hippocampal neurons in an isoform-dependent manner. J Neurosci 1995;15:2157-2167
18. Schubert D, Jin LW, Saitoh T, Cole G. The regulation of amyloid beta protein precursor secretion and its modulatory role in cell adhesion. Neuron 1989;3:689-694
19. Sinha S, Dovey HF, Seubert P, et al. The protease inhibitory properties of the Alzheimer's beta-amyloid precursor protein. J Biol Chem 1990;265:8983-8985
20. Smith RP, Higuchi DA, Broze GJ Jr. Platelet coagulation factor XIa-inhibitor, a form of Alzheimer amyloid precursor protein. Science 1990;248:1126-1128
21. Buxbaum JD, Liu KN, Luo Y, et al. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 1998;273:27765-27767
22. Koike H, Tomioka S, Sorimachi H, et al. Membrane-anchored metalloprotease MDC9 has an alpha-secretase activity responsible for processing the amyloid precursor protein. Biochem J 1999;343:371-375
23. Lammich S, Kojro E, Postina R, et al. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci U S A 1999;96:3922-3927
24. Esch FS, Keim PS, Beattie EC, et al. Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science 1990;248:1122-1124
25. Sisodia SS, Koo EH, Beyreuther K, Unterbeck A, Price DL. Evidence that beta-amyloid protein in Alzheimer's disease is not derived by normal processing. Science 1990;248:492-495
26. Hussain I, Powell D, Howlett DR, et al. Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci 1999;14:419-427
27. Sinha S, Anderson JP, Barbour R, et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 1999;402:537-540
28. Vassar R, Bennett BD, Babu-Khan S, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999;286:735-741
29. Yan R, Bienkowski MJ, Shuck ME, et al. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 1999;402:533-537
30. Seubert P, Oltersdorf T, Lee MG, et al. Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide. Nature 1993;361:260-263
31. Haass C, Koo EH, Mellon A, Hung AY, Selkoe DJ. Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature 1992;357:500-503
32. Gravina SA, Ho L, Eckman CB, et al. Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J Biol Chem 1995;270:7013-7016
33. Iwatsubo T, Odaka A, Suzuki N, et al. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 1994;13:45-53
34. Jarrett JT, Berger EP, Lansbury PT Jr. The C-terminus of the beta protein is critical in amyloidogenesis. Ann N Y Acad Sci 1993;695:144-148
35. Tamaoka A, Kondo T, Odaka A, et al. Biochemical evidence for the long-tail form (A beta 1-42/43) of amyloid beta protein as a seed molecule in cerebral deposits of Alzheimer's disease. Biochem Biophys Res Commun 1994;205:834-842
36. Funato H, Yoshimura M, Kusui K, et al. Quantitation of amyloid beta-protein (A beta) in the cortex during aging and in Alzheimer's disease. Am J Pathol 1998;152:1633-1640
37. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001;81:741-766
38. Selkoe DJ. Alzheimer's disease: genotypes, phenotypes, and treatments. Science 1997;275:630-631
39. Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci U S A 1995;92:4725-4727
40. Grundke-Iqbal I, Iqbal K, Tung YC, et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 1986;83:4913-4917
41. Kosik KS, Joachim CL, Selkoe DJ. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci U S A 1986;83:4044-4048
42. Nukina N, Ihara Y. One of the antigenic determinants of paired helical filaments is related to tau protein. J Biochem (Tokyo) 1986;99:1541-1544
43. Gomez-Isla T, Hollister R, West H, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 1997;41:17-24
44. Hyman BT, Van Horsen GW, Damasio AR, Barnes CL. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science 1984;225:1168-1170
45. Gomez-Isla T, West HL, Rebeck GW, et al. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Ann Neurol 1996;39:62-70
46. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 1997;20:154-159
47. Borchelt DR, Thinakaran G, Eckman CB, et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 1996;17:1005-1013
48. Citron M, Westaway D, Xia W, et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 1997;3:67-72
49. Duff K, Eckman C, Zehr C, et al. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 1996;383:710-713
50. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996;2:864-870
51. Edbauer D, Winkler E, Regula JT, et al. Reconstitution of gamma-secretase activity. Nat Cell Biol 2003;5:486-488
52. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 1993;90:1977-1981
53. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997;278:1349-1356
54. Rubinsztein DC, Easton DF. Apolipoprotein E genetic variation and Alzheimer's disease. a meta-analysis. Dement Geriatr Cogn Disord 1999;10:199-209
55. Wilson C, Wardell MR, Weisgraber KH, Mahley RW, Agard DA. Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science 1991;252:1817-1822
56. Marz W, Peschke B, Ruzicka V, et al. Type III hyperlipoproteinemia acquired by liver transplantation. Transplantation 1993;55:284-288
57. Garcia MA, Vazquez J, Gimenez C, Valdivieso F, Zafra F. Transcription factor AP-2 regulates human apolipoprotein E gene expression in astrocytoma cells. J Neurosci 1996;16:7550-7556
58. Nakai M, Kawamata T, Taniguchi T, Maeda K, Tanaka C. Expression of apolipoprotein E mRNA in rat microglia. Neurosci Lett 1996;211:41-44
59. Zannis VI, Breslow JL. Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification. Biochemistry 1981;20:1033-1041
60. Beffert U, Poirier J. Apolipoprotein E, plaques, tangles and cholinergic dysfunction in Alzheimer's disease. Ann N Y Acad Sci 1996;777:166-174
61. Nagy Z, Esiri MM, Jobst KA, et al. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience 1995;69:757-761
62. Ohm TG, Kirca M, Bohl J, et al. Apolipoprotein E polymorphism influences not only cerebral senile plaque load but also Alzheimer-type neurofibrillary tangle formation. Neuroscience 1995;66:583-587
63. Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A 1993;90:9649-9653
64. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins - an integrated approach to mechanisms and disorders. N Engl J Med 1967;276:273-281 concl
65. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins - an integrated approach to mechanisms and disorders. N Engl J Med 1967;276:215-225 contd
66. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins - an integrated approach to mechanisms and disorders. N Engl J Med 1967;276:148-156 contd
67. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins - an integrated approach to mechanisms and disorders. N Engl J Med 1967;276:94-103 contd
68. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins - an integrated approach to mechanisms and disorders. N Engl J Med 1967;276:34-42 contd
69. Mann WA, Meyer N, Weber W, et al. Apolipoprotein E isoforms and rare mutations: parallel reduction in binding to cells and to heparin reflects severity of associated type III hyperlipoproteinemia. J Lipid Res 1995;36:517-525
70. Marz W, Hoffmann MM, Scharnagl H, et al. Apolipoprotein E2 (Arg136 → Cys) mutation in the receptor binding domain of apoE is not associated with dominant type III hyperlipoproteinemia. J Lipid Res 1998;39:658-669
71. Koch S, Donarski N, Goetze K, et al. Characterization of four lipoprotein classes in human cerebrospinal fluid. J Lipid Res 2001;42:1143-1151
72. Gong JS, Kobayashi M, Hayashi H, et al. Apolipoprotein E (ApoE) isoform-dependent lipid release from astrocytes prepared from human ApoE3 and ApoE4 knock-in mice. J Biol Chem 2002;277:29919-29926
73. Sun Y, Wu S, Bu G, et al. Glial fibrillary acidic protein-apolipoprotein E (apoE) transgenic mice: astrocyte-specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins. J Neurosci 1998;18:3261-3272
74. Strittmatter WJ, Weisgraber KH, Huang DY, et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A 1993;90:8098-8102
75. Wisniewski T, Golabek A, Matsubara E, Ghiso J, Frangione B. Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid. Biochem Biophys Res Commun 1993;192:359-365
76. Chan W, Fornwald J, Brawner M, Wetzel R. Native complex formation between apolipoprotein E isoforms and the Alzheimer's disease peptide A beta. Biochemistry 1996;35:7123-7130
77. Yang DS, Smith JD, Zhou Z, Gandy SE, Martins RN. Characterization of the binding of amyloid-beta peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma. J Neurochem 1997;68:721-725
78. Zhou Z, Smith JD, Greengard P, Gandy S. Alzheimer amyloid-beta peptide forms denaturant-resistant complex with type epsilon 3 but not type epsilon 4 isoform of native apolipoprotein E. Mol Med 1996;2:175-180
79. Scharnagl H, Tisljar U, Winkler K, et al. The betaA4 amyloid peptide complexes to and enhances the uptake of beta-very low density lipoproteins by the low density lipoprotein receptor-related protein and heparan sulfate proteoglycans pathway. Lab Invest 1999;79:1271-1286
80. Winkler K, Scharnagl H, Tisljar U, et al. Competition of Abeta amyloid peptide and apolipoprotein E for receptor-mediated endocytosis. J Lipid Res 1999;40:447-455
81. 2 techniques in vivo and in vitro. J Biol Chem 1997;272:30178-30184
82. Lutjohann D, Breuer O, Ahlborg G, et al. Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc Natl Acad Sci U S A 1996;93:9799-9804
83. Pitas RE, Boyles JK, Lee SH, Foss D, Mahley RW. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta 1987;917:148-161
84. Pitas RE, Boyles JK, Lee SH, Hui D, Weisgraber KH. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J Biol Chem 1987;262:14352-14360
85. Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 1996;383:728-731
86. Lehmann JM, Kliewer SA, Moore LB, et al. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem 1997;272:3137-3140
87. Kolsch H, Ludwig M, Lutjohann D, Rao ML. Neurotoxicity of 24-hydroxycholesterol, an important cholesterol elimination product of the brain, maybe prevented by vitamin E and estradiol-17beta. J Neural Transm 2001;108:475-488
88. Papassotiropoulos A, Lutjohann D, Bagli M, et al. 24S-Hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J Psychiatr Res 2002;36:27-32
89. Bogdanovic N, Bretillon L, Lund EG, et al. On the turnover of brain cholesterol in patients with Alzheimer's disease. Abnormal induction of the cholesterol-catabolic enzyme CYP46 in glial cells. Neurosci Lett 2001;314:45-48
90. Bretillon L, Lutjohann D, Stahle L, et al. Plasma levels of 24S-hydroxycholesterol reflect the balance between cerebral production and hepatic metabolism and are inversely related to body surface. J Lipid Res 2000;41:840-845